Published in Drug Week, July 2nd, 2004
The findings provide promising evidence that researchers can activate a patient's own immune system to fight advanced melanoma.
"This is the first time we have evaluated peptide-derived melanoma vaccine results from a multicenter cooperative group trial," said John Kirkwood, MD, principal investigator of the study, professor of medicine at the University of Pittsburgh and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.